Qing-Re-Xiao-Zheng-Yi-Qi formula relieves kidney damage and activates mitophagy in diabetic kidney disease

Qiaoru Wu, Runze Yan, Hanwen Yang, Yixuan Wang, Chao Zhang, Jiale Zhang, Zhaoli Cui, Yaoxian Wang, Sun Weiwei, Weiwei SunFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates the therapeutic mechanisms of the traditional Chinese medicine formula Qing-Re-Xiao-Zheng-Yi-Qi (QRXZYQF) in treating diabetic kidney disease (DKD). The research reveals that QRXZYQF not only alleviates kidney damage and fibrosis but also activates mitophagy, a crucial cellular process for clearing damaged mitochondria, thereby protecting podocytes.

What Problem Does This Paper Address?

Diabetic kidney disease (DKD) is a severe complication of diabetes, leading to significant morbidity and mortality worldwide. While its pathogenesis is complex, involving hyperglycemia, oxidative stress, and inflammation, leading to renal fibrosis and eventual kidney failure, current treatments often fall short. Traditional Chinese Medicine (TCM) offers a promising avenue, with QRXZYQF showing clinical efficacy. However, the precise molecular mechanisms underlying QRXZYQF's protective effects in DKD, particularly its impact on cellular quality control mechanisms like mitophagy, remained unclear. This paper aims to elucidate these mechanisms, focusing on how QRXZYQF might combat DKD by addressing both the pathological damage and the underlying cellular dysfunction.

Methods

The researchers employed a multi-faceted approach:

  • Chemical Profiling: They used Vanquish UHPLC™ to identify the chemical constituents present in the freeze-dried QRXZYQF powder, revealing 27 tentatively identified compounds.
  • DKD Model Creation: A rat model of DKD was established through unilateral nephrectomy followed by high-dose streptozotocin (STZ) injection to induce hyperglycemia.
  • In Vivo Assessment: DKD rats were treated with QRXZYQF, and their physiological parameters (body weight, renal index, blood glucose, serum creatinine, BUN, lipids, total protein, albumin, liver enzymes) and renal pathology were assessed. Histological analysis (HE, Masson, PAS staining) and transmission electron microscopy (TEM) were used to evaluate kidney damage and fibrosis.
  • Molecular Analysis: Western blot analysis was performed on kidney tissues to quantify the levels of fibrosis-related proteins (Col IV, TGF-β1) and mitophagy-related proteins (PINK1, Parkin, LC3, P62).
  • In Vitro Studies: A cell culture model using mouse podocytes (MPC5) exposed to high glucose was used to further investigate the effects of QRXZYQF on podocyte health and mitophagy. Immunofluorescence co-localization was employed to visualize and quantify mitophagy.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and cell cultures.

Key Insights and Ideas

  • Mitophagy as a Key Target: The study strongly suggests that impaired mitophagy is a significant contributor to DKD pathogenesis, and QRXZYQF's therapeutic benefit is, in part, mediated by its ability to restore this crucial cellular process.
  • Dual Action of QRXZYQF: The formula demonstrates a dual therapeutic action: it directly mitigates the pathological hallmarks of DKD (fibrosis, proteinuria) and simultaneously enhances cellular resilience by promoting mitophagy.
  • PINK1/Parkin Pathway Activation: The research pinpoints the PINK1/Parkin pathway as a critical target of QRXZYQF in activating mitophagy, a pathway known to be dysregulated in DKD.
  • Podocyte Protection: The study highlights that QRXZYQF's ability to activate mitophagy is directly linked to protecting podocytes, the specialized cells in the kidney glomerulus essential for filtration.

Key Results

  • Chemical Composition: 27 constituents of QRXZYQF were identified, providing a chemical basis for its therapeutic effects.
  • Physiological Improvements: QRXZYQF treatment in DKD rats led to increased body weight, reduced renal index, improved glycolipid metabolism (lower BUN, glucose, TG), reduced proteinuria (24h-UTP), and ameliorated liver enzyme levels.
  • Renal Pathology Attenuation: Histological analysis showed that QRXZYQF reduced glomerular hypertrophy, tubulointerstitial injury, fibrosis (Masson staining), and glomerulosclerosis (PAS staining). TEM revealed less mitochondrial damage and foot process effacement in podocytes.
  • Fibrosis Reduction: QRXZYQF significantly decreased the expression of fibrosis markers Col IV and TGF-β1.
  • Nephrin Upregulation: The expression of nephrin, a key podocyte marker, was increased by QRXZYQF treatment, indicating improved podocyte integrity.
  • Mitophagy Activation: In both in vivo and in vitro models, QRXZYQF treatment was shown to increase the expression of PINK1 and Parkin, reduce the LC3-II/LC3-I ratio, and decrease P62 levels, all indicative of activated PINK1/Parkin-mediated mitophagy. Immunofluorescence confirmed increased mitophagosome formation.

Limitations and Future Work

  • Conflicting Mitophagy Data: The authors acknowledge that existing literature shows conflicting results regarding mitophagy in different DKD models (e.g., inhibition vs. activation). They attribute this to variations in serum glucose levels and experimental durations, suggesting that the stage of diabetes might influence mitophagy dynamics.
  • Identifying Active Components: QRXZYQF is a multi-component formula, making it challenging to pinpoint the specific ingredient(s) responsible for the observed effects. Future work will focus on identifying key bioactive components and their associated bioactivity assays.
  • Further Mechanistic Exploration: While the study elucidates the role of mitophagy, further research is needed to fully understand the intricate mechanisms by which QRXZYQF intervenes in DKD.

The study provides a strong foundation for understanding QRXZYQF's therapeutic potential in DKD, highlighting mitophagy activation as a novel and promising therapeutic strategy.

Summary updated

Abstract

<b>Introduction:</b> Qing-Re-Xiao-Zheng-Yi-Qi Formula is an effective prescription in diabetic kidney disease treatment, we have confirmed the efficacy of Qing-Re-Xiao-Zheng therapy in diabetic kidney disease through clinical trials. In this study, we investigated the mechanisms of Qing-Re-Xiao-Zheng-Yi-Qi Formula in the treatment of diabetic kidney disease. <b>Methods:</b> We used Vanquish UHPLC<sup>TM</sup> to analyze the chemical profiling of Qing-Re-Xiao-Zheng-Yi-Qi Formula freeze-dried powder. We constructed diabetic kidney disease rat models induced by unilateral nephrectomy and high-dose streptozocin injection. We examined blood urea nitrogen, serum creatinine, serum glucose, total cholesterol, triglyceride, serum total protein, albumin, alanine aminotransferase, aspartate aminotransferase and 24 h urinary total protein in diabetic kidney disease rats. The renal pathological changes were observed by HE, Masson, PAS stanning and transmission electron microscopy. The levels of fibrosis-related proteins and mitophagy-related proteins were detected by western blot analysis. We also conducted an immunofluorescence co-localization analysis on podocytes to further investigate the effect of Qing-Re-Xiao-Zheng-Yi-Qi Formula treatment on mitophagy. <b>Results:</b> A total of 27 constituents in Qing-Re-Xiao-Zheng-Yi-Qi Formula were tentatively identified. We found PINK1/Parkin-mediated mitophagy was inhibited in diabetic kidney disease. Qing-Re-Xiao-Zheng-Yi-Qi Formula treatment could raise body weight and reduce renal index, reduce proteinuria, improve glycolipid metabolic disorders, ameliorate renal fibrosis, and reduce the expression of Col Ⅳ and TGF-β1 in diabetic kidney disease rats. Qing-Re-Xiao-Zheng-Yi-Qi Formula treatment could also increase the expression of nephrin, activate mitophagy and protect podocytes in diabetic kidney disease rats and high glucose cultured podocytes. <b>Conclusion:</b> PINK1/Parkin-mediated mitophagy was inhibited in diabetic kidney disease, and Qing-Re-Xiao-Zheng-Yi-Qi Formula treatment could not only ameliorate pathological damage, but also promote mitophagy to protect podocytes in diabetic kidney disease.
BibTeX
@inproceedings{wu2022qing,
  author = {Qiaoru Wu and Runze Yan and Hanwen Yang and Yixuan Wang and Chao Zhang and Jiale Zhang and Zhaoli Cui and Yaoxian Wang and Sun Weiwei and Yaoxian Wang and Weiwei Sun},
  title = {{Qing-Re-Xiao-Zheng-Yi-Qi formula relieves kidney damage and activates mitophagy in diabetic kidney disease}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.992597},
}
Figure